Ország: Egyesült Államok
Nyelv: angol
Forrás: NLM (National Library of Medicine)
SELEGILINE HYDROCHLORIDE (UNII: 6W731X367Q) (SELEGILINE - UNII:2K1V7GP655)
Zoetis Inc.
SELEGILINE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE 2 mg
ORAL
PRESCRIPTION
Anipryl tablets are indicated for the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS) and control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH). Anipryl is contraindicated in patients with known hypersensitivity to this drug. In humans, selegiline is contraindicated for use with meperidine and this contraindication is often extended to other opioids.
Four tablet strengths are available in blister-packs of 30 tablets each: 5 mg, 10 mg, 15 mg, and 30 mg. Each box contains 1 blister pack (30 tablets).
New Animal Drug Application
ANIPRYL- SELEGILINE HYDROCHLORIDE TABLET ZOETIS INC. ---------- ANIPRYL ANIPRYL (selegiline hydrochloride tablets) For use in dogs only CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION Anipryl (selegiline hydrochloride tablets) are white, convex tablets containing 5, 10, 15, and 30 mg of selegiline HCl. It is commonly referred to in the clinical and pharmacological literature as L-deprenyl (the levorotatory form of deprenyl HCl). Selegiline hydrochloride is (—)-_(R)_-_N_,α-Dimethyl-_N_-2-propynylphenethylamine hydrochloride. Molecular Formula: C H N HCl Molecular Weight: 223.75 PHARMACOLOGY Selegiline is an irreversible inhibitor of monoamine oxidase (MAO). MAOs are widely distributed throughout the body and are subclassified into 2 types, A and B, which differ in their substrate specificity and tissue distribution. Selegiline is believed to be a selective inhibitor of MAO-B at recommended dosages in the dog due to its greater affinity for type B enzyme active sites compared to type A sites. In CNS neurons, MAO plays a role in the catabolism of catecholamines, (dopamine, and, to a lesser extent, norepinephrine and epinephrine) and serotonin. Selegiline may have pharmacologic effects unrelated ® ® 13 17 1,2 1 1,2 to MAO-B inhibition. There is some evidence that it may increase dopaminergic activity by other mechanisms, including increasing synthesis and release of dopamine into the synapse as well as interfering with dopamine re-uptake from the synapse. Effects resulting from selegiline administration may also be mediated through its metabolites. Two of its 3 principal metabolites, L-amphetamine and L-methamphetamine, have pharmacologic actions of their own. However, the extent to which these metabolites contribute to the effects of selegiline is unknown. Therapeutic effects of selegiline are thought to result in part from enhanced catecholaminergic nerve function and increased dopamine levels in the CNS. The pathogenesis of the development of clinical Olvassa el a teljes dokumentumot